Omadacyclin (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Omadacyclin" in German language version.

refsWebsite
Global rank German rank
2nd place
3rd place
4th place
7th place
447th place
751st place
406th place
1,055th place
407th place
1,458th place
low place
low place
2,614th place
3,424th place

bizjournals.com

doi.org

  • Laura Honeyman, Mohamed Ismail, Mark L Nelson, Beena Bhatia, Todd E. Bowser: Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. In: Antimicrobial Agents and Chemotherapy. Band 59, Nr. 11, 2015, S. 7044–7053, doi:10.1128/AAC.01536-15, PMID 26349824, PMC 4604364 (freier Volltext).
  • S Ken Tanaka, Stephen Villano: In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. In: Antimicrobial Agents and Chemotherapy. Band 60, Nr. 9, 22. August 2016, S. 5247–5253, doi:10.1128/AAC.00320-16, PMID 27324778, PMC 4997885 (freier Volltext).
  • Stephen Villano, Judith Steenbergen, Evan Loh: Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. In: Future Microbiology. Band 11, 2016, S. 1421–1434, doi:10.2217/fmb-2016-0100, PMID 27539442.
  • A B. Macone, B K Caruso, R G Leahy, J Donatelli, S Weir: In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. In: Antimicrobial Agents and Chemotherapy. Band 58, Nr. 2, 2014, S. 1127–1135, doi:10.1128/AAC.01242-13, PMID 24295985, PMC 3910882 (freier Volltext).
  • Jimmy Flarakos, Yancy Du, Helen Gu, Lai Wang, Heidi J Einolf: Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. In: Xenobiotica; the Fate of Foreign Compounds in Biological Systems. Band 47, Nr. 8, 2017, S. 682–696, doi:10.1080/00498254.2016.1213465, PMID 27499331.
  • Michael P Draper, S Weir, A Macone, J Donatelli, C A Trieber: Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline. In: Antimicrobial Agents and Chemotherapy. Band 58, Nr. 3, 2014, S. 1279–1283, doi:10.1128/AAC.01066-13, PMID 24041885, PMC 3957880 (freier Volltext).
  • Gary J Noel, Michael P Draper, Howard Hait, S Ken Tanaka, Robert D Arbeit: A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections. In: Antimicrobial Agents and Chemotherapy. Band 56, Nr. 11, 2012, S. 5650–5654, doi:10.1128/AAC.00948-12, PMID 22908151, PMC 3486554 (freier Volltext).
  • William O’Riordan, Sinikka Green, J Scott Overcash, Ivan Puljiz, Symeon Metallidis: Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. In: New England Journal of Medicine. Band 380, Nr. 6, 7. Februar 2019, S. 528–538, doi:10.1056/NEJMoa1800170.
  • Fredrick M Abrahamian, George Sakoulas, Evan Tzanis, Amy Manley, Judith N Steenbergen: 1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials. In: Open Forum Infectious Diseases. Band 5, Suppl 1, 26. November 2018, S. S412, doi:10.1093/ofid/ofy210.1178, PMC 6253360 (freier Volltext).
  • Roman Stets, Monica Popescu, Joven R Gonong, Ismail Mitha, William Nseir: Omadacycline for Community-Acquired Bacterial Pneumonia. In: New England Journal of Medicine. Band 380, Nr. 6, 7. Februar 2019, S. 517–527, doi:10.1056/NEJMoa1800201.
  • M J Fine, T E Auble, D M Yealy, B H Hanusa, L A Weissfeld: A prediction rule to identify low-risk patients with community-acquired pneumonia. In: The New England Journal of Medicine. Band 336, Nr. 4, 23. Januar 1997, S. 243–250, doi:10.1056/NEJM199701233360402, PMID 8995086.

fda.gov

globenewswire.com

nih.gov

ncbi.nlm.nih.gov

  • Laura Honeyman, Mohamed Ismail, Mark L Nelson, Beena Bhatia, Todd E. Bowser: Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. In: Antimicrobial Agents and Chemotherapy. Band 59, Nr. 11, 2015, S. 7044–7053, doi:10.1128/AAC.01536-15, PMID 26349824, PMC 4604364 (freier Volltext).
  • S Ken Tanaka, Stephen Villano: In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. In: Antimicrobial Agents and Chemotherapy. Band 60, Nr. 9, 22. August 2016, S. 5247–5253, doi:10.1128/AAC.00320-16, PMID 27324778, PMC 4997885 (freier Volltext).
  • Stephen Villano, Judith Steenbergen, Evan Loh: Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. In: Future Microbiology. Band 11, 2016, S. 1421–1434, doi:10.2217/fmb-2016-0100, PMID 27539442.
  • A B. Macone, B K Caruso, R G Leahy, J Donatelli, S Weir: In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. In: Antimicrobial Agents and Chemotherapy. Band 58, Nr. 2, 2014, S. 1127–1135, doi:10.1128/AAC.01242-13, PMID 24295985, PMC 3910882 (freier Volltext).
  • Jimmy Flarakos, Yancy Du, Helen Gu, Lai Wang, Heidi J Einolf: Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. In: Xenobiotica; the Fate of Foreign Compounds in Biological Systems. Band 47, Nr. 8, 2017, S. 682–696, doi:10.1080/00498254.2016.1213465, PMID 27499331.
  • Michael P Draper, S Weir, A Macone, J Donatelli, C A Trieber: Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline. In: Antimicrobial Agents and Chemotherapy. Band 58, Nr. 3, 2014, S. 1279–1283, doi:10.1128/AAC.01066-13, PMID 24041885, PMC 3957880 (freier Volltext).
  • Gary J Noel, Michael P Draper, Howard Hait, S Ken Tanaka, Robert D Arbeit: A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections. In: Antimicrobial Agents and Chemotherapy. Band 56, Nr. 11, 2012, S. 5650–5654, doi:10.1128/AAC.00948-12, PMID 22908151, PMC 3486554 (freier Volltext).
  • Fredrick M Abrahamian, George Sakoulas, Evan Tzanis, Amy Manley, Judith N Steenbergen: 1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials. In: Open Forum Infectious Diseases. Band 5, Suppl 1, 26. November 2018, S. S412, doi:10.1093/ofid/ofy210.1178, PMC 6253360 (freier Volltext).
  • M J Fine, T E Auble, D M Yealy, B H Hanusa, L A Weissfeld: A prediction rule to identify low-risk patients with community-acquired pneumonia. In: The New England Journal of Medicine. Band 336, Nr. 4, 23. Januar 1997, S. 243–250, doi:10.1056/NEJM199701233360402, PMID 8995086.

prnewswire.com

ptcommunity.com